Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 10.9%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBGet Free Report) was the target of a large decrease in short interest in April. As of April 30th, there was short interest totalling 17,900 shares, a decrease of 10.9% from the April 15th total of 20,100 shares. Based on an average trading volume of 5,600 shares, the days-to-cover ratio is currently 3.2 days. Currently, 0.2% of the company’s shares are short sold.

Anebulo Pharmaceuticals Stock Performance

Anebulo Pharmaceuticals stock opened at $2.35 on Thursday. Anebulo Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $4.05. The firm has a market capitalization of $60.23 million, a price-to-earnings ratio of -5.60 and a beta of -0.98. The company has a 50 day moving average price of $2.75 and a 200 day moving average price of $2.53.

Anebulo Pharmaceuticals (NASDAQ:ANEBGet Free Report) last issued its earnings results on Tuesday, February 13th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Equities analysts forecast that Anebulo Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

(Get Free Report)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Featured Articles

Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with's FREE daily email newsletter.